The clinical effectiveness of REGEN-COV in SARS-CoV-2 infection with Omicron versus Delta variants

DOI record: { "DOI": "10.1371/journal.pone.0278770", "ISSN": [ "1932-6203" ], "URL": "http://dx.doi.org/10.1371/journal.pone.0278770", "abstract": "<jats:sec id=\"sec001\">\n<jats:title>Background</jats:title>\n<jats:p>In vitro studies suggesting that REGEN-COV (casirivimab plus imdevimab monoclonal antibodies) had poor efficacy against Omicron-variant SARS-CoV-2 infection led to amendment of REGEN-COV’s Emergency Use Authorization to recommend use only in regions without high Omicron prevalence. REGEN-COV’s relative clinical effectiveness for Omicron is unknown.</jats:p>\n</jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods and findings</jats:title>\n<jats:p>We conducted a retrospective cohort study of non-hospitalized adults who tested positive for SARS-CoV-2 by polymerase chain reaction at the University of Miami Health System from July 19 –November 21, 2021 (Delta period) and December 6, 2021 –January 7, 2022 (Omicron period). Subjects were stratified be REGEN-COV receipt within 72h of test positivity and by time period of infection. We constructed multivariable logistic regression models to assess the differential association of REGEN-COV receipt with hospitalization within 30 days (primary outcome) and ED presentation; all models included three exposure terms (REGEN-COV receipt, Omicron vs Delta period, interaction of REGEN-COV with time period) and potential confounders (vaccination status, vaccine boosting, cancer diagnosis). Our cohort consisted of 2,083 adults in the Delta period (213 [10.2%] received REGEN-COV) and 4,201 in the Omicron period (156 [3.7%] received REGEN-COV). Hospitalization was less common during the Omicron period than during Delta (0.9% vs 1.7%, p = 0.78) and more common for patients receiving REGEN-COV than not (5.7% vs 0.9%, p&lt;0.001). After adjustment, we found no differential association of REGEN-COV use during Omicron vs Delta with hospitalization within 30d (adjusted odds ratio [95% confidence interval] for the interaction term: 2.31 [0.76–6.92], p = 0.13). Similarly, we found no differential association for hospitalization within 15d (2.45 [0.63–9.59], p = 0.20) or emergency department presentation within 30d (1.43 [0.57–3.51], p = 0.40) or within 15d (1.79 [0.65–4.82], p = 0.30).</jats:p>\n</jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Conclusions</jats:title>\n<jats:p>Within the limitations of this study’s power to detect a difference, we identified no differential effectiveness of REGEN-COV in the context of Omicron vs Delta SARS-CoV-2 infection.</jats:p>\n</jats:sec>", "author": [ { "ORCID": "http://orcid.org/0000-0002-7360-2489", "affiliation": [], "authenticated-orcid": true, "family": "Gershengorn", "given": "Hayley B.", "sequence": "first" }, { "affiliation": [], "family": "Patel", "given": "Samira", "sequence": "additional" }, { "affiliation": [], "family": "Ferreira", "given": "Tanira", "sequence": "additional" }, { "affiliation": [], "family": "Das", "given": "Sankalp", "sequence": "additional" }, { "affiliation": [], "family": "Parekh", "given": "Dipen J.", "sequence": "additional" }, { "affiliation": [], "family": "Shukla", "given": "Bhavarth", "sequence": "additional" } ], "container-title": "PLOS ONE", "container-title-short": "PLoS ONE", "content-domain": { "crossmark-restriction": false, "domain": [ "www.plosone.org" ] }, "created": { "date-parts": [ [ 2022, 12, 2 ] ], "date-time": "2022-12-02T18:25:55Z", "timestamp": 1670005555000 }, "deposited": { "date-parts": [ [ 2022, 12, 2 ] ], "date-time": "2022-12-02T18:26:17Z", "timestamp": 1670005577000 }, "editor": [ { "affiliation": [], "family": "Thanachartwet", "given": "Vipa", "sequence": "first" } ], "funder": [ { "name": "University of Miami Hospital and Clinics Data Analytics Research Team" }, { "name": "University of Miami Hospital and Clinics Data Analytics Research Team" }, { "name": "University of Miami Hospital and Clinics Data Analytics Research Team" }, { "name": "University of Miami Hospital and Clinics Data Analytics Research Team" }, { "name": "University of Miami Hospital and Clinics Data Analytics Research Team" }, { "name": "University of Miami Hospital and Clinics Data Analytics Research Team" } ], "indexed": { "date-parts": [ [ 2022, 12, 3 ] ], "date-time": "2022-12-03T06:03:37Z", "timestamp": 1670047417289 }, "is-referenced-by-count": 0, "issue": "12", "issued": { "date-parts": [ [ 2022, 12, 2 ] ] }, "journal-issue": { "issue": "12", "published-online": { "date-parts": [ [ 2022, 12, 2 ] ] } }, "language": "en", "license": [ { "URL": "http://creativecommons.org/licenses/by/4.0/", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2022, 12, 2 ] ], "date-time": "2022-12-02T00:00:00Z", "timestamp": 1669939200000 } } ], "link": [ { "URL": "https://dx.plos.org/10.1371/journal.pone.0278770", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "340", "original-title": [], "page": "e0278770", "prefix": "10.1371", "published": { "date-parts": [ [ 2022, 12, 2 ] ] }, "published-online": { "date-parts": [ [ 2022, 12, 2 ] ] }, "publisher": "Public Library of Science (PLoS)", "reference": [ { "author": "JA O’Shaughnessy", "key": "pone.0278770.ref001", "volume-title": "Emergency Use Authorization 091", "year": "2022" }, { "DOI": "10.1056/NEJMoa2108163", "article-title": "REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19", "author": "DM Weinreich", "doi-asserted-by": "crossref", "first-page": "e81", "issue": "23", "journal-title": "N Engl J Med", "key": "pone.0278770.ref002", "volume": "385", "year": "2021" }, { "DOI": "10.1126/scitranslmed.abn8543", "article-title": "SARS-CoV-2 BA.1 variant is neutralized by vaccine booster-elicited serum but evades most convalescent serum and therapeutic antibodies", "author": "S Lusvarghi", "doi-asserted-by": "crossref", "first-page": "eabn8543", "issue": "645", "journal-title": "Sci Transl Med", "key": "pone.0278770.ref003", "volume": "14", "year": "2022" }, { "DOI": "10.1038/s41591-021-01678-y", "article-title": "An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies", "author": "LA VanBlargan", "doi-asserted-by": "crossref", "first-page": "490", "issue": "3", "journal-title": "Nat Med", "key": "pone.0278770.ref004", "volume": "28", "year": "2022" }, { "DOI": "10.1038/s41586-021-04385-3", "article-title": "Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies", "author": "Y Cao", "doi-asserted-by": "crossref", "first-page": "657", "issue": "7898", "journal-title": "Nature", "key": "pone.0278770.ref005", "volume": "602", "year": "2022" }, { "article-title": "Clinical efficacy and in vitro neutralization capacity of monoclonal antibodies for SARS-CoV-2 delta and omicron variants", "author": "TT Brehm", "journal-title": "J Med Virol", "key": "pone.0278770.ref006", "year": "2022" }, { "DOI": "10.1128/spectrum.00926-22", "article-title": "Susceptibility of SARS-CoV-2 Omicron Variants to Therapeutic Monoclonal Antibodies: Systematic Review and Meta-analysis.", "author": "K Tao", "doi-asserted-by": "crossref", "first-page": "e0092622", "journal-title": "Microbiol Spectr.", "key": "pone.0278770.ref007", "year": "2022" }, { "article-title": "Visualizing the omicron wave striking and rolling across the country.", "author": "D Keating", "first-page": "2022", "journal-title": "The Washington Post.", "key": "pone.0278770.ref008", "volume": "28", "year": "2022" }, { "DOI": "10.1016/0895-4356(92)90133-8", "article-title": "Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases.", "author": "RA Deyo", "doi-asserted-by": "crossref", "first-page": "613", "issue": "6", "journal-title": "J Clin Epidemiol", "key": "pone.0278770.ref009", "volume": "45", "year": "1992" }, { "DOI": "10.1038/s41586-021-03720-y", "article-title": "In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains", "author": "RE Chen", "doi-asserted-by": "crossref", "first-page": "103", "issue": "7870", "journal-title": "Nature", "key": "pone.0278770.ref010", "volume": "596", "year": "2021" }, { "DOI": "10.1007/s40121-021-00525-4", "article-title": "Efficacy of Bamlanivimab/Etesevimab and Casirivimab/Imdevimab in Preventing Progression to Severe COVID-19 and Role of Variants of Concern.", "author": "M Falcone", "doi-asserted-by": "crossref", "first-page": "2479", "issue": "4", "journal-title": "Infect Dis Ther.", "key": "pone.0278770.ref011", "volume": "10", "year": "2021" }, { "DOI": "10.1136/bmj-2022-070695", "article-title": "Risk of covid-19 related deaths for SARS-CoV-2 omicron (B.1.1.529) compared with delta (B.1.617.2): retrospective cohort study.", "author": "IL Ward", "doi-asserted-by": "crossref", "first-page": "e070695", "journal-title": "BMJ", "key": "pone.0278770.ref012", "volume": "378", "year": "2022" }, { "DOI": "10.1056/NEJMc2206576", "article-title": "Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5", "author": "NP Hachmann", "doi-asserted-by": "crossref", "first-page": "86", "issue": "1", "journal-title": "N Engl J Med", "key": "pone.0278770.ref013", "volume": "387", "year": "2022" } ], "reference-count": 13, "references-count": 13, "relation": {}, "resource": { "primary": { "URL": "https://dx.plos.org/10.1371/journal.pone.0278770" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [ "Multidisciplinary" ], "subtitle": [], "title": "The clinical effectiveness of REGEN-COV in SARS-CoV-2 infection with Omicron versus Delta variants", "type": "journal-article", "update-policy": "http://dx.doi.org/10.1371/journal.pone.corrections_policy", "volume": "17" }